Lew Makings

Vertex Pharmaceuticals (United States)

Papers

1

Total Citations

160

H-Index

1

About

Lew Makings has fundamentally advanced the field of high-throughput drug discovery through his pioneering work in assay development for protein kinases and phosphatases. His most influential contribution, the 2002 paper "A FRET-Based Assay Platform for Ultra-High Density Drug Screening of Protein Kinases and Phosphatases," has garnered over 160 citations and established a cornerstone methodology for studying signal transduction. Makings recognized that protein phosphorylation governs critical cellular events—from proliferation and apoptosis to metabolism—and that aberrant kinase or phosphatase activity underlies numerous diseases. By engineering a robust fluorescence resonance energy transfer (FRET) platform, he enabled ultra-high density screening, dramatically accelerating the identification of therapeutic compounds targeting these enzymes. This work bridged fundamental biochemistry with practical drug discovery, providing researchers with a scalable, sensitive tool to probe phosphorylation dynamics. Makings’ contributions have proven essential for both academic labs investigating signaling pathways and pharmaceutical companies seeking novel kinase inhibitors, cementing his reputation as a key innovator in assay technology and chemical biology.

Research Focus

Key Achievements

1
H-Index
1
Papers
160
Total Citations
160
Avg Citations/Paper
🏆 Most Cited Paper
A FRET-Based Assay Platform for Ultra-High Density Drug Screening of Protein Kinases and Phosphatases
160 citations · 2002
📈 Most Prolific Year: 2002 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: Vertex Pharmaceuticals (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago